Abstract：Objective To monitor the drug resistance of tuberculosis in Zhejiang Province and to provide scientific evidence for the control of drug resistant tuberculosis.Methods Thirty counties in Zhejiang Province were selected as sample during July 1, 2013 and June 30 2014, and smear positive cases were selected to be monitored during study period.Results The rate of drug resistance was 30.88%, and the rate of multi drug resistance was 5.02%. The rate of the extensively drug-resistant tuberculosis was 0.32%. Among initial treatment cases, the rate of drug resistance was 29.22%, higher than 2008, and the rate of multi drug resistance was 3.21%.Among retreatment cases, the rate of drug resistance was 45.74%, and the rate of multi drug resistance was 21.28%. All kinds of monitored drugs were found resistance phenomenon. The drug resistant rate of SM was highest (15.28%), and aminoglycosides (2.35%) were relatively low.Conclusion The status of retreatment TB drug resistance suggested that we had reduced acquired TB drug resistance through implementation of DOTS strategy and standard short course chemotherapy treatment in Zhejiang Province. But it is still not optimistic to control TB drug resistance, and the status of initial treatment TB resistant suggested that resistant strains spread had not been effectively controlled in Zhejiang Province. So we should strengthen the early detection of drug resistant among TB patients,and to further improve the standard of conventional TB treatment.
陈松华, 吴蓓蓓, 柳正卫, 何海波, 潘爱珍, 王飞, 张明五, 周琳, 张钰, 王晓萌. 浙江省结核病耐药状况分析[J]. 预防医学, 2016, 28(8): 757-761,765.
CHEN Song-hua, WU Bei-bei, LIU Zheng-wei, HE Hai-bo, PAN Ai-zhen, WANG Fei, ZHANG Ming-wu, ZHOU lin, ZHANG Yu, WANG Xiao-meng. An analysis on the epidemic characteristics of tuberculosis drug resistance in Zhejiang Province. Preventive Medicine, 2016, 28(8): 757-761,765.
[1]World Health Organization. Hepatitis B [R]. Geneva: World Health Organization, 2015.
[2]郭敏建,姚军,李静.成人乙肝疫苗不同免疫程序效果观察[J].浙江预防医学, 2015,27(8):757-760.
[3]WHO.Hepatitis B vaccines: WHO position paper[J]. Weekly epidemiological record, 2009,84(40):405-420.
[4]庄贵华,颜虹,王学良.乙型肝炎疫苗接种无应答解决对策[J].中华预防医学杂志,2007,41(5):403-406.
[5]GHEBREHEWET S, BAXTER D, FALCONER M, et al. Intradermal recombinant hepatitis B vaccination(IDRV) for non-responsive healthcare workers(HCWs)[J]. Hum Vaccin. 2008,4(4):280-285.
[6]陈胜玉,王学才,董晓莲,等.成人重组酵母乙肝疫苗两种不同免疫程序接种效果观察[J].中国预防医学杂志,2013,14(2):96-98.
[7]ZHANG W, HAN L,LIN C,et al. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell(CHO) hepatitis B vaccine[J]. Vaccine,2011,29(37): 6276-6282.
[8]蒋汝刚,付翔,周静,等.成年人接种乙肝疫苗后无(弱)应答状况及其影响因素分析[J].中华疾病控制杂志,2011,15(3):210-212.
[9]RAMEZANI A, AGHASADEGHI M R, AHMADI F,et al.Isolated anti-HBc and occult HBV infection in dialysis patients[J]. Nephro-urology Monthly,2015,7(1):e22674.
[10]叶贤林,杜鹏,冯旭,等.深圳市18～25岁抗-HBc阳性合格献血者隐匿性乙肝病毒感染的血清学和分子生物学特性分析[J].中国输血杂志,2014,11(27):1112-1115.
[11]GESSONI G, BEGGIO S, BARIN P,et al. Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination[J]. Blood Transfus,2014,12(1):S63-S68.
[12]周波青,徐峰,张艳,等.不同免疫程序成人重组乙型肝炎疫苗(汉逊酵母)接种免疫效果比较研究[J].中国疫苗和免疫,2015,21(5):495-498.
[13]YAO J,LI J,CHEN Y,et al. The response of hepatitis B vaccination on seronegative adults with different vaccination schedules[J].Human Vaccines and Immunotherapeutics,2015,11(5):1102-1107.
[14]吕静静,颜丙玉,陈士玉,等.成人乙型肝炎疫苗初免低应答后加强免疫及影响因素分析[J].山东大学学报(医学版),2012,50(11):126-132.
[15]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病学杂志,2011,19(1):13-24.
[16]曾滢,宋雪芳,潘红星,等.成人乙肝疫苗无应答者复种效果研究[C].第五次全国免疫诊断暨疫苗学术研讨会论文汇编,2011.
[17]杨培娟.大学生乙型肝炎疫苗无应答者再免疫一剂60 μg疫苗的效果观察[J].中华预防医学杂志,2013,47(10):966-967.
